Sign up to save your podcasts
Or
Share Research to Advance ASO Technology at n-Lorem
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Research to Advance ASO Technology at n-Lorem
At n-Lorem, every investment decision carries real weight by directly affecting the nano-rare patients we serve. We think very deeply about each decision of how to invest the limited and precious dollars that we have. But what about investing in basic research to advance antisense oligonucleotide (ASO) technology for the future? Certainly, most of the money should and is being put towards creating ASOs to help patients in need today. Meanwhile, it is also our belief that we must invest to continue innovating and, in this episode, we explore the research occurring at n-Lorem today that will lead to better treatments for more nano-rare patients tomorrow.
On this episode we discuss:
- ASO technology is still evolving unlike other validated drug discovery technologies
- Nano-rare patients need more from ASO technology
- Reasons n-Lorem are unable to help more patients
- Solutions to these challenges are possible and we know how to do it
Links:
Colloquium - https://www.nlorem.org/nano-rare-patient-colloquium-2025/
Donate - https://www.nlorem.org/donate/
View all episodes
By n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen)
5
3030 ratings
At n-Lorem, every investment decision carries real weight by directly affecting the nano-rare patients we serve. We think very deeply about each decision of how to invest the limited and precious dollars that we have. But what about investing in basic research to advance antisense oligonucleotide (ASO) technology for the future? Certainly, most of the money should and is being put towards creating ASOs to help patients in need today. Meanwhile, it is also our belief that we must invest to continue innovating and, in this episode, we explore the research occurring at n-Lorem today that will lead to better treatments for more nano-rare patients tomorrow.
On this episode we discuss:
- ASO technology is still evolving unlike other validated drug discovery technologies
- Nano-rare patients need more from ASO technology
- Reasons n-Lorem are unable to help more patients
- Solutions to these challenges are possible and we know how to do it
Links:
Colloquium - https://www.nlorem.org/nano-rare-patient-colloquium-2025/
Donate - https://www.nlorem.org/donate/
More shows like Patient Empowerment Program: A Rare Disease Podcast
View all
This American Life
90,949 Listeners
Embedded
12,026 Listeners
The Daily
111,917 Listeners
Crime Junkie
366,047 Listeners
The Readout Loud
318 Listeners
The Weekly Show with Jon Stewart
10,613 Listeners
BioSpace
10 Listeners